文献速递特殊人群用药治疗药物监测与药物基因组学

新生儿及小婴儿CYP2C19发育药物基因组学:奥美拉唑探针研究

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.
PubMed 文献 · Br J Clin Pharmacol · 2018-03-09

本研究基于51名接受奥美拉唑治疗的高加索新生儿及小婴儿,采用群体药代动力学-药物基因组学方法定量描述CYP2C19的发育药物基因组学。结果显示奥美拉唑转化为5-羟基奥美拉唑的清除率随出生后日龄增加,CYP2C19慢代谢和中间代谢者的该清除率分别仅为快/超快代谢者的12.5%和44.9%。

要点

  • 奥美拉唑代谢清除率随出生后日龄增加,提示新生儿CYP2C19活性呈发育性变化。
  • CYP2C19慢代谢者奥美拉唑代谢清除率显著低于快/超快代谢者。
  • ABCB1基因多态性可能影响奥美拉唑吸收速率常数。

核心结论

  • 采用奥美拉唑探针可定量描述新生儿及小婴儿CYP2C19的发育药物基因组学。
  • 研究强调对于多途径生物转化药物,评估发育药物基因组学时应采用半生理发育药代动力学建模方法。

研究设计与样本

  • 群体药代动力学-药物基因组学研究,纳入51名接受奥美拉唑治疗的高加索新生儿及小婴儿。
  • 使用NONMEM对奥美拉唑及其代谢物进行群体药代动力学-药物基因组学分析。

主要发现

  • 数据符合一室母药和代谢物模型,一级吸收和消除。
  • CYP2C19和CYP3A4主要参与奥美拉唑代谢,尽管其活性相对成人较低。
  • 奥美拉唑转化为5-羟基奥美拉唑的清除率(CLOMZ-M1)随出生后日龄增加。
  • CYP2C19慢代谢者和中间代谢者的模型预测CLOMZ-M1分别为快/超快代谢者的12.5%(5-95%百分位:3-14.9%)和44.9%(5-95%百分位:29.9-72.6%)。
  • ABCB1纯合突变患者的奥美拉唑模型预测吸收速率常数为纯合野生型的6.93倍(5-95%百分位:3.01-14.61),杂合突变患者为1.86倍(5-95%百分位:0.86-3.47)。

临床怎么用

  • 新生儿及小婴儿使用奥美拉唑时需考虑CYP2C19基因型和出生后日龄对代谢的影响。
  • CYP2C19慢代谢和中间代谢的新生儿及小婴儿奥美拉唑代谢清除率显著降低,可能需关注药物蓄积风险。

局限性

  • 研究样本为51名高加索新生儿及小婴儿,结果外推至其他种族人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Although substantial progress has been made in understanding of ontogeny of drug metabolism, there is still a gap of knowledge in developmental pharmacogenetics in neonates. We hypothesized that both age and pharmacogenetics might explain the developmental pattern of CYP2C19. We conducted a population pharmacokinetic-pharmacogenetic study to quantify the developmental pharmacogenetics of CYP2C19 in neonates and young infants using omeprazole as a probe drug. METHODS: Pharmacokinetic samples were collected from 51 Caucasian neonates and young infants, who were receiving omeprazole treatment. Population pharmacokinetic-pharmacogenetic analysis of omeprazole and its metabolites was performed using NONMEM. RESULTS: Data fitted a one-compartment parent and metabolite model with first-order absorption and elimination. CYP2C19 and CYP3A4 are predominantly involved in the metabolism of omeprazole despite their relatively low activities compared to adults. The clearance of omeprazole converted to 5-hydroxy-omeprazole (CLOMZ-M1 ) increases with postnatal age. In CYP2C19 poor and intermediate metabolizers, model-predicted CLOMZ-M1 are 12.5% (5-95% percentile: 3-14.9%) and 44.9% (5-95% percentile: 29.9-72.6%) of the value in extensive/ultrarapid metabolizer, respectively. Model-predicted absorption rate constant of omeprazole is 6.93 (5-95% percentile: 3.01-14.61) times higher in ABCB1 homozygous mutant patients, 1.86 (5-95% percentile: 0.86-3.47) times higher in ABCB1 heterozygous patients than that in ABCB1 homozygous wild-type patients. CONCLUSIONS: Developmental pharmacogenetics of CYP2C19 was quantitatively described in neonates and young infants using omeprazole as a probe drug. Our findings emphasize the importance of semiphysiological developmental pharmacokinetic modelling approach when evaluating developmental pharmacogenetics of drugs with multiple routes of biotransformation.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhao W, Leroux S, Biran V, et al. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. Br J Clin Pharmacol. 2018. PMID: 29377228. doi:10.1111/bcp.13526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。